Smart Pain Relief Starts Here
Developing a nerve-selective therapy designed to interrupt pain near the source
Relief that lasts. Lives that move forward.
At Brixton, we’re focused on improving the lives of people suffering from pain.
Initially focusing on musculoskeletal indications, Brixton’s flagship product, Reneurx™ Nerve-Selective Therapy, is an innovative solution to pain management – designed to provide targeted and durable relief without the potential risks associated with opioids or corticosteroids.
The first indication for Reneurx therapy is focused on chronic pain associated with knee osteoarthritis. With approximately 24M people in the US affected by this condition, this new solution could provide millions with durable pain relief.
Our current pipeline includes programs for pain associated with knee osteoarthritis, lateral hip pain, thumb joint pain, and migraine.
We’re led by a team with extensive experience in the life sciences and a track record of successfully translating ambitious, innovative science into life-changing realities for patients.
Pain relief at the source
Based upon research from Massachusetts General Hospital, Reneurx therapy was designed to physically disrupt pain signaling at the nerve level.
Reneurx therapy is a unique biomaterial that, when injected locally around a target treatment area at approximately –10°C, physically disrupts the lipid rich myelin sheath, interrupting pain transmission while sparing surrounding tissues.
Clinical data demonstrates that patients with symptomatic knee osteoarthritis experience 6 months of meaningful pain relief.
